Target Price | JPY1,795.45 |
Price | JPY1,458.50 |
Potential |
23.10%
register free of charge
|
Number of Estimates | 11 |
11 Analysts have issued a price target Astellas Pharma 2026 .
The average Astellas Pharma target price is JPY1,795.45.
This is
23.10%
register free of charge
JPY2,400.00
64.55%
register free of charge
JPY1,400.00
4.01%
register free of charge
|
|
A rating was issued by 12 analysts: 4 Analysts recommend Astellas Pharma to buy, 7 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Astellas Pharma stock has an average upside potential 2026 of
23.10%
register free of charge
|
Mar '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion JPY | 1,603.67 | 1,889.38 |
5.60% | 17.82% | |
EBITDA Margin | 20.95% | 20.93% |
18.68% | 0.08% | |
Net Margin | 1.06% | 0.33% |
83.41% | 68.88% |
11 Analysts have issued a sales forecast Astellas Pharma 2025 . The average Astellas Pharma sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an Astellas Pharma EBITDA forecast 2025. The average Astellas Pharma EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Astellas Pharma Analysts have issued a net profit forecast 2025. The average Astellas Pharma net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Mar '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share JPY | 9.50 | 3.49 |
82.49% | 63.26% | |
P/E | 417.91 | |
EV/Sales | 1.83 |
6 Analysts have issued a Astellas Pharma forecast for earnings per share. The average Astellas Pharma <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Astellas Pharma stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Astellas Pharma...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.